CRP and metastatic neoplasm: Nakamura et al. examined the role of pre-treatment CRP levels and NLR in a cohort of 129 patients with non-metastatic disease, and observed significantly worse disease-specific survival outcomes for patients with both an elevated CRP level and high NLR, as compared to those with both a normal CRP level and low NLR12.